Article Contents ::
- 1 The Brand Name LANCEPRED Has Generic Salt :: Prednisolone
- 2 LANCEPRED Is From Company Lancer Priced :: Rs. 7.00/14.00
- 3 LANCEPRED have Prednisolone is comes under Sub class Corticosteroids of Main Class Endocrine,Steroid Hormones , Metabolic System
- 4 Main Medicine Class:: Endocrine,Steroid Hormones , Metabolic System Sub Medicine Class :: Corticosteroids
- 5 Disclaimer ::
The Brand Name LANCEPRED Has Generic Salt :: Prednisolone
LANCEPRED Is From Company Lancer Priced :: Rs. 7.00/14.00
LANCEPRED have Prednisolone is comes under Sub class Corticosteroids of Main Class Endocrine,Steroid Hormones , Metabolic System
Main Medicine Class:: Endocrine,Steroid Hormones , Metabolic System Sub Medicine Class :: Corticosteroids
|Salt Name : OR Generic Name||Form||Price : MRP /Probable||Packing|
Indications for Drugs ::
Rheumatoid arthritis, Multiple sclerosis, Allergic and inflammatory disorders, Nephrotic syndrome, Idiopathic thrombocytopenic purpura, Joint inflammations, Moderate to severe asthma, Infantile spasms
Drug Dose ::
Oral Allergic and inflammatory disorders Adult: 5-60 mg daily in 2-4 divided doses. Maintenance: 2.5-15 mg daily. Withdrawal should be gradual after long-term therapy. Child: 1 mth-18 yr: Autoimmune inflammatory disorders: Initially, 1-2 mg/kg once daily; may reduce dose gradually after a few days if needed. Max: 60 mg daily. Autoimmune hepatitis: Initially, 2 mg/kg once daily, then reduce to minimum effective dose. Max: 40 mg daily. Poorly controlled, moderate to severe asthma Adult: Patients with at least 2 exacerbations/yr requiring oral corticosteroids: 40-60 mg daily in 1-2 divided doses; usually given as a short course treatment over 3-10 days until symptom resolution and patient achieves a peak expiratory flow (PEF) of at least 80% of his or her personal best. May be used with maintenance dosages of inhaled corticosteroid and a long-acting inhaled ?2-agonist bronchodilator. Child: Patients with >3 exacerbations/yr in children ?4 yr or at least 2 exacerbations/yr in children 5-11 yr: 1-2 mg/kg daily for 3-5 days may be used with existing asthma treatment; dose may be given in 1-2 divided doses. Max: 60 mg daily. Nephrotic syndrome Child: 1 mth-18 yr: Initially, 60 mg/m2 (max: 80 mg) once daily for 4 wk until urine is protein-free followed by 40 mg/m2 every other day for 4 wk, then withdraw dose gradually. Prevention of relapse: 0.5-1 mg/kg once daily every other day for 3-6 mth. Rheumatoid arthritis Adult: Initially, 5-7.5 mg daily, adjusted as necessary. Elderly: 5 mg daily. Multiple sclerosis Adult: 200 mg daily for 1 wk followed by 80 mg every other day for 1 mth. Infantile spasms Child: 1 mth-2 yr: Initially, 10 mg 4 times daily for 14 days; increase to 20 mg 3 times daily for 7 days if seizures are not controlled after 7 days; reduce dose slowly over 15 days until therapy is stopped. For patients taking 40 mg daily, reduce dose in steps of 10 mg every 5 days, then stop; in patients taking 60 mg daily, reduce dose to 40 mg daily for 5 days, then 20 mg daily for 5 days, then 10 mg daily for 5 days, then stop. Idiopathic thrombocytopenic purpura Child: 1-10 yr: 1-2 mg/kg daily (max: 14 days) or 4 mg/kg daily (max: 4 days).
Live vaccines; herpes simplex keratitis, systemic infections.
Drug Precautions ::
Patients with hypothyroidism, cirrhosis, ulcerative colitis, CHF, convulsive disorders, thrombophlebitis, peptic ulcer, elderly. DM, hypertension, psychological disturbances, osteoporosis; pregnancy, lactation. Adrenal suppression and infection. May cause irreversible growth retardation, glaucoma, corneal perforation.
Drug Side Effects ::
Cushing’s syndrome and growth retardation in childn; osteoporosis, fractures. Peptic ulceration; glaucoma, cataracts; hyperglycaemia, pancreatitis; increased appetite, obesity. Potentially Fatal: Acute adrenal insufficiency precipitated by infection, trauma or surgery in patients on long-term therapy or following cessation of such therapy. CV collapse following rapid IV injection.
Pregnancy category ::
Drug Mode of Action ::
Prednisolone decreases inflammation by inhibition of migration of polymorphonuclear leukocytes and reversal of increased capillary permeability. It suppresses the immune system by reducing the activity and production of the lymphocytes and eosinophils.
Drug Interactions ::
Efficacy may be reduced by phenytoin, phenobarb, rifampicin. Corticoids may reduce the effects of diuretics, hypoglycaemics, anticholinesterases, salicylates.